KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial

Prior treatment

• Intravitreal injection of anti-VEGF drugs within 3 month before enrollment;
• Those who plan to receive ocular surgery during the follow-up period;

Other illness

• Suffering from other ocular diseases that affect ocular examinations (e.g. keratopathy, uveitis, intraocular infection, etc.);
• Having other systemic diseases such as severe liver and kidney function damage, cardiovascular disorders, respiratory disorders, etc.) that may affect the anti-neovascular effect of KDR2-2 or more likely to develop adverse events ;
• Systemic infections under treatment;
• Any study in which the physician believes that the patient's condition will interfere with the clinical trial (e.g., the patient is prone to stress, mood disorders, depression, etc.);

Other

• Participation in other clinical trials within 1 month;
• Premenopausal women without birth control;

• Age 18-75;
• The best-corrected visual acuity (BCVA) of the included eyes was \<0.01 (Snellen chart);
• The BCVA of the contralateral eye of the included subjects was \>0.1;
• Patients with clinically diagnosed neovascular glaucoma; The diagnostic criteria for neovascularization glaucoma were as follows: Intraocular pressure \> 21mmHg measured by Goldmann applanation tonometer; Neovascularization is seen in the iris or anterior chamber angle, with or without corneal edema;
• Compliance with follow up for more than 28 days and written informed consent obtained;